Blood testing nears its turning point as evidence mounts by Conor Hale Friday, December 20, 2019 The field has seen setbacks, but a steady march of clinical data and engineering successes have shown that these ideas can work when done right.
Guardant's cancer blood test receives expanded Medicare coverage by Conor Hale Thursday, December 19, 2019 Guardant received an expanded Medicare determination for its Guardant360 test, broadening its coverage to all solid tumors outside of the CNS.
Guardant blood test tracks MSI on par with tissue biopsy: study by Conor Hale Monday, August 5, 2019 Guardant Health’s blood test could provide an easier way to predict a cancer patient’s response to immunotherapy across multiple solid tumors.
Resolution assay beats Guardant360 in complex gene fusion study by Conor Hale Monday, April 1, 2019 A retrospective study of Resolution’s blood test and Guardant360 found that it was able to detect a greater number of actionable mutations in NSCLC.
Guardant to pick up epigenome gumshoe Bellwether Bio by Conor Hale Thursday, March 28, 2019 Guardant Health has moved to acquire Bellwether Bio, which focuses on early cancer diagnostics that tap into the epigenomics of cell-free DNA.
Guardant blood test outperforms tissue biopsy in landmark study by Conor Hale Thursday, February 28, 2019 A head-to-head study found Guardant’s lung cancer blood test delivered similar results much faster and with more accuracy in first-line NSCLC.
M&A, IPOs and VC raises: Biotech, medtech execs look to 2019 by Amirah Al Idrus, Conor Hale, Ben Adams Friday, January 11, 2019 What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
Guardant unveils epigenetic research test for early-stage cancer by Conor Hale Tuesday, January 8, 2019 SAN FRANCISCO—Guardant Health has launched a new epigenetic liquid biopsy test for researchers aimed at spotting cancer in its early stages.
Guardant to develop blood tests for AstraZeneca’s targeted drugs by Conor Hale Friday, December 14, 2018 AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.
Guardant Health discloses cyberattack alongside planned IPO by Conor Hale Monday, September 10, 2018 In its IPO filing, Guardant Health disclosed it had received a cyberattack, with hackers accessing the personal information of about 1,100 patients.
